This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Uran (benannt nach dem Planeten Uranus) ist ein chemisches Element mit dem Elementsymbol U und der Ordnungszahl 92. Im Periodensystem steht es in der Gruppe der Actinoide (7. Periode, f-Block). Uran ist ein Metall, dessen sämtliche Isotope radioaktiv sind. Natürlich in Mineralen auftretendes Uran besteht zu etwa 99,3 % aus dem Isotop 238U und zu 0,7 % aus 235U. Eine besondere Bedeutung erhielt Uran nach der Entdeckung der Kernspaltung im Jahre 1938. Das Uranisotop 235U ist durch thermische Neutronen spaltbar und damit – neben dem äußerst seltenen, aber aus Uran erzeugbaren Plutonium-Isotop 239Pu – das einzige natürlich vorkommende Nuklid, mit dem eine selbsterhaltende Kernspaltungs-Kettenreaktion möglich ist. Daher findet es Verwendung als Primärenergieträger in Kernkraftwerken und Kernwaffen.
Uran wurde 1789 von dem deutschen, damals in Berlin lebenden, Chemieprofessor und Apotheker Martin Heinrich Klaproth aus dem Mineral Pechblende isoliert. Klaproth selbst benannte es nach dem Planeten Uranus (und somit nach dem griechischen Himmelsgott Uranos), der acht Jahre zuvor (1781) von Friedrich Wilhelm Herschel entdeckt worden war. Am 24. September 1789 gab Klaproth die Entdeckung in einer Ansprache vor der Preußischen Akademie der Wissenschaften bekannt. Zuerst wurde seine Entdeckung Uranit genannt, 1790 dann in Uranium umbenannt. Klaproth hatte seine Entdeckung bei der Analyse des Erzes aus dem Bergwerk „Georg Wagsfort“ in Wittigsthal bei Johanngeorgenstadt in Sachsen gemacht. Er behandelte das Erz mit Säure und erwärmte es stark. Das Ergebnis bestand in einem schwarzen Pulver, welches er Uran nannte. Klaproth hatte tatsächlich ein neues Element identifiziert, aber was er gewonnen hatte, war nicht das Element Uran selbst, sondern ein Oxid. Erst fünfzig Jahre später im Jahre 1841 gelang es dem Franzosen Eugène Peligot, reines Uranmetall zu gewinnen. In der ersten Hälfte des 19. Jahrhunderts wurde Uran zusammen mit anderen Mineralien in St. Joachimsthal sowie in einigen Minen in Cornwall (England) gewonnen.
Uranverbindungen wurden im ganzen 19. Jahrhundert zum Färben von Glas und Keramik verwendet, um Vasen und Dekorationsstücken, aber auch alltäglichen Gebrauchsgegenständen wie Schüsseln, Gläsern eine gelbgrüne Farbe („annagrün“) zu geben. Glashersteller in Joachimsthal (Böhmen) benutzten diese Technik bereits 1826. Noch bis in die Mitte des 20. Jahrhunderts wurde Uran zur Glasfärbung genutzt, erst dann wurde es durch andere, weniger bedenkliche farbgebende Mineralien ersetzt. Uranhaltige keramische Glasuren von Orange bis leuchtend Rot wurden für Geschirr bis hin zu architektonischem Beiwerk verwendet. Diese in den USA aufgrund des Namens eines Herstellers „Fiestaware“ genannte Keramik gehört wohl (neben Americium-Rauchmeldern) zu den radioaktivsten Gegenständen, welche noch immer in vielen amerikanischen Haushalten zu finden sind. In der Photographie diente bis weit ins 20. Jahrhundert Uranylnitrat zur Braun- und Rottonung von Diapositivplatten, Platinbildern und Bromsilberbildern. Dass Uran radioaktiv ist, wurde 1896 zuerst von Antoine Henri Becquerel festgestellt. Uran galt lange als das Element mit der höchsten Ordnungszahl, das natürlich vorkommt. Im Jahr 1971 wurden jedoch winzigste Spuren des Plutoniumisotops 244Pu nachgewiesen, weshalb Plutonium (Z = 94) Uran als natürliches Element mit der höchsten Ordnungszahl ablöste.
Uran kommt nicht gediegen in der Natur vor, sondern stets in sauerstoffhaltigen Mineralen. Bedeutende Uranminerale sind unter anderem Brannerit und Uraninit (Oxide), Torbernit, Heinrichit und Carnotit (Phosphate, Arsenate und Vanadate) sowie Coffinit und Uranophan (Silikate). Es gibt insgesamt rund 230 Uranminerale, die lokal ebenfalls von wirtschaftlicher Bedeutung sein können. In sedimentären Lagerstätten können sich auch Pseudomorphosen von Uranmineralen (meist Uraninit in Form von Pechblende) nach fossilem Holz oder Bakterien bilden. Die beiden entscheidenden Faktoren für die Verteilung des radioaktiven Elements Uran auf der Erde sind zum einen der lithophile Charakter des Elements sowie seine unterschiedliche Mobilität in wässrigen Lösungen unter oxidierenden und reduzierenden Bedingungen. Der lithophile Charakter sorgt dafür, dass Uran sich in silikatreichen Schmelzen anreichert. Daher enthalten in der Regel felsische Magmatite wie Granit als Plutonit oder Rhyolith als Vulkanit die höchsten Konzentrationen dieses Elements. Die kontinentale Kruste ist der Bereich der Erde mit den höchsten Urangehalten von durchschnittlich 2,5 ppm, während die ozeanische Kruste und der Erdmantel um Größenordnungen geringere Urangehalte aufweisen. In magmatischen Gesteinen wird Uran meist in akzessorische Minerale wie Zirkon oder Monazit eingebaut, mit welchen man daher sehr gut das Alter der Gesteine datieren kann.
Sources: de.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.